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Alzheimer’s disease (AD) is a progres-
sive neurodegenerative disorder and the
leading cause of cognitive and behav-
ioral impairment in industrialized soci-
eties. The cause of AD is unknown and
the major risk factor for AD is age. About
5% of all AD cases have a genetic or famil-
ial cause however the vast majority of all
AD cases (∼95%) are of sporadic ori-
gin. Both the familial and the sporadic
forms of AD share a common disease
phenotype involving at least eight char-
acteristic features including (i) evidence
of uncontrolled oxidative stress; (ii) up-
regulated pro-inflammatory signaling; (iii)
changes in innate-immune signaling; (iv)
the progressive accumulation of lesions
including neurofibrillary tangles (NFT)
and amyloid beta (Aβ)-containing senile
plaques (SP); (v) significant synaptic sig-
naling deficits; (vi) neurite and brain cell
atrophy; (vii) progressively altered gene
expression patterns that are different from
healthy brain aging; and (viii) progressive
cognitive impairment and dementia in the
host. There is currently no cure or ade-
quate clinical treatment for AD, and it
remains unclear how AD originates and
propagates throughout the brain and cen-
tral nervous system (CNS). Results from
recent genome-wide association studies
(GWAS) indicate that a significant portion
of AD-relevant gene signals are not located
within gene coding regions suggesting the
contribution of epigenetic or environ-
mental factors to AD risk. The potential
contribution of pathogenic microbes to
aging and AD is becoming increasingly
recognized (Miklossy, 2011; Cho and
Blaser, 2012; Bhattacharjee and Lukiw,
2013; Poole et al., 2013; Heintz and Mair,
2014; Huang et al., 2014; Mancuso et al.,
2014). Importantly, most of the changes
seen in AD, such as inflammation, brain
cell atrophy, immunological aberrations,
amyloidogenesis, altered gene expression
and cognitive deficits are also seen as a
consequence of microbial infection (Cho
and Blaser, 2012; Yatsunenko et al., 2012;
Bhattacharjee and Lukiw, 2013; Foster
and McVey Neufeld, 2013; Kim et al.,
2013; Heintz and Mair, 2014; Mancuso
et al., 2014). This brief communication
will review some recent observations on
the potential contribution of pathogens
to neurological dysfunction, with specific
reference to AD wherever possible.
Firstly, humans contain a complex and
dynamic community of microbes called
the microbiome that forms a “metaor-
ganism” with symbiotic or commensal
benefit to the host (Cho and Blaser, 2012;
Bhattacharjee and Lukiw, 2013; Heintz
and Mair, 2014). The microbiome of the
human gastrointestinal (GI) tract con-
tains the largest reservoir of microbes,
containing about 1014 microbes from at
least 1000 distinct microbial species, and
outnumbering human host cells by about
100 to 1 (Whitman et al., 1998; Kim et al.,
2013). The GI tract microbiome has been
estimated to encode about 4 × 106 genes
so the quantity of the microbiome genes
outnumbers host genes by about 150 to
1 (Bhattacharjee and Lukiw, 2013). Over
99% of GI tract microbiota are anaerobic
bacteria, with fungi, protozoa, archaebac-
teria and other microorganisms making
up the remainder; interestingly only two
bacterial divisions are prominent in GI
tract microbiota, including Firmicutes
(∼51%) and Bacteroidetes (∼48%), with
the remaining 1% of phylotypes dis-
tributed amongst the Cyanobacteria,
Fusobacteria, Proteobacteria, Spirochaetes,
and Verrucomicrobia, with various species
of fungi, protozoa, viruses and other
microorganisms making up the remainder
(http://www.genome.gov/pages/research/
sequencing/seqproposals/hgmiseq.pdf).
Of all human GI tract microbiota, bacte-
rial densities of up to 1012 per ml are the
highest recorded density in any known
microbial ecosystem (Whitman et al.,
1998; Bhattacharjee and Lukiw, 2013; Kim
et al., 2013). Interestingly, the microor-
ganisms making up the smallest 1% of
the microbiome have a disproportion-
ately large effect on disease, and it is a
major function of the healthy GI tract
microbiome to keep under control the
proliferation of any potentially pathogenic
microbes contained within (Hornig, 2013;
Kim et al., 2013; Heintz and Mair, 2014;
see below).
Recent interest in the role of the micro-
biome in human health and disease has
rapidly expanded over the last several
years with the advent of new sequenc-
ing and bioinformatics technologies for
interrogating the genetics of complex
microbial communities and microbial-
host interactions. There is currently
much interest in the ability of GI tract
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bacteria to influence host innate-immune,
neuroinflammatory-, neuromodulatory-
and neurotransmission-functions (Bravo
et al., 2012; Bhattacharjee and Lukiw,
2013; Boutajangout andWisniewski, 2013;
Brenner, 2013; Douglas-Escobar et al.,
2013; Heintz and Mair, 2014; Mancuso
et al., 2014). While potentially pathogenic
GI tract microbes are kept in check
by a homeostatic commensalism, their
increased abundance has been associ-
ated with diseases that include anxiety,
autoimmune-disease, diabetes, metabolic-
syndrome, obesity, and stress-induced
and progressive neuropsychiatric dis-
eases including autism, schizophrenia and
AD (Bravo et al., 2012; Bhattacharjee
and Lukiw, 2013; Boutajangout and
Wisniewski, 2013; Foster and McVey
Neufeld, 2013; Hornig, 2013; Heintz and
Mair, 2014).
Here we list 10 recent, highly specific
and illustrative insights into the poten-
tial contribution of pathogenic microbes,
altered microbiome signaling and other
disease-inducing agents to the develop-
ment of AD:
(1) Fungal infection of the CNS: AD is
characterized in part by amyloid-
containing senile plaques (SPs)
and neurofibrillary tangles (NFTs)
that induce microglial cell activa-
tion, neuroinflammation and brain
and neurovascular cell dysfunction.
Recently yeast and fungal proteins
including (1,3)-β-glucan, high levels
of fungal polysaccharides and dis-
seminated and diffuse mycoses in
the peripheral blood of AD patients
suggests that chronic fungal infec-
tionsmay increase AD risk (Prusiner,
2013; Alonso et al., 2014; Heintz and
Mair, 2014). It is interesting that
amyloids are associated with the
surface structures of fungi which
may aid in their organization and
promote higher order assembly of
amyloid (Liu et al., 2008; Asti and
Gioglio, 2014).
(2) HSV-1 is associated with AD:
Abundant evidence suggests that
the double-stranded DNA (dsDNA)
herpes simplex virus-1 (HSV-1), a
neurotrophic, neuroinvasive mem-
ber of the family Herpesviridae
can establish lifelong latency in
CNS tissues and contribute to AD
(Jamieson et al., 1991; Kammerman
et al., 2006; Itzhaki and Wozniak,
2008; Toma et al., 2008; Lukiw et al.,
2010; Ball et al., 2012; Agostini
et al., 2014; Mancuso et al., 2014).
A particularly interesting obser-
vation is that when human brain
cells are infected with HSV-1, there
is a significant and selective up-
regulation in the expression of a
small non-coding single-stranded
RNA (ssRNA) known as miRNA-
146a. This pro-inflammatory
miRNA is also significantly up-
regulated in anatomical areas of
the human brain affected with
AD and in human prion diseases
where it contributes to altered
innate-immune responses (Lukiw
et al., 2010; Prusiner, 2013). It
is noteworthy that of all ∼2000
known miRNAs the same inducible,
pro-inflammatory miRNA-146a is
specifically up-regulated in both
AD and in HSV-1 infected brain
cells (Hill and Lukiw, 2014). Besides
host-encoded miRNAs, ∼200 virally
encoded miRNAs have been dis-
covered in dsDNA viruses (mainly
HSV-1 and polyomoviruses)—these
regulate fundamental biological
processes including immune recog-
nition, promotion of cell survival,
angiogenesis, cell proliferation and
differentiation, but their contribu-
tion to the AD process is not well
understood (Plaisance-Bonstaff and
Renne, 2011).
(3) Prion diseases: driven by an unusual
type of self-replicating “microbe,”
prion diseases are sporadic, inher-
ited or acquired and ultimately
fatal neurological disorders highly
similar to AD (Lukiw et al., 2011;
Prusiner, 2013). Aβ peptide “prion-
like” aggregates induce widespread
amyloidogenesis after inoculation
into susceptible animal hosts (Stöhr
et al., 2012; Prusiner, 2013). The
recent discovery that prions can
serve as Aβ receptors to relay amyloid
neurotoxicity, and that peripherally
administrated prions reach the brain,
has engendered renewed interest in
this self-replicating protein and its
involvement in AD-like signaling
processes that include neuroinflam-
mation, synaptic degeneration and
amyloidogenesis (Prusiner, 2013;
Chen et al., 2014; Hernandez-Rapp
et al., 2014).
(4) Chlamydophila pneumoniae, other
pathogenic bacteria and AD: The
association of the gram negative,
obligate intracellular bacteria and
pneumonia-causing C. pneumoniae
of the family Chlamydiaceae with
diseases such as coronary artery
disease, arthritis, multiple sclero-
sis, meningoencephalitis, and AD
has recently gained serious atten-
tion (Balin and Hudson, 2014;
Wunderink and Waterer, 2014).
Atypical extracellular C. pneumo-
niae antigens in the neocortex of AD
brain and their association with SP
and NFT suggest the contribution
of C. pneumoniae infection to AD
pathology (Hammond et al., 2010;
Choroszy-Król et al., 2014). It is
interesting to note that virtually all
AD patients expire from pneumonia
as a cause of death and not as a direct
consequence of AD itself (Choroszy-
Król et al., 2014; Huston et al.,
2014). Interestingly, other recent
studies have further implicated
Borrelia species, Helicobacter pylori,
the periodontopathic spirochaete
Treponema denticola, Tannerella
forsythia, Porphyromonas gingivalis
and other bacteria with increased
incidence of age-related dementias
including AD (Miklossy, 2011; Poole
et al., 2013; Huang et al., 2014).
(5) HIV-1 and AD: Human immunod-
eficiency virus (HIV), a lentivirus
of the family Retroviridae, is a
slowly replicating virion containing
a 9749 nucleotide ssRNA genome
that causes acquired immunod-
eficiency syndrome (AIDS)—a
condition in which progressive fail-
ure of the immune system allows
opportunistic infection (Borjabad
and Volsky, 2012; Risacher and
Saykin, 2013). HIV-associated neu-
rocognitive disorders (HAND)
is a common manifestation of
HIV infection and encompasses a
variety of neurological disorders
including AIDS dementia complex,
HIV-associated encephalopathy and
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AIDS-associated cognitive decline
(Borjabad and Volsky, 2012; Widera
et al., 2014). Histopathologically
HIV-infected brains exhibit atro-
phy of neurites and neuronal loss
in anatomical areas identical to
what is seen in AD (Widera et al.,
2014). Recent comparative meta-
analysis further indicate that brains
of patients with HAND and AD
share common mis-regulated gene
expression profiles implicating
altered neuroimmune responses
and progressive deficits in synaptic
transmission (Borjabad and Volsky,
2012). Conversely, Aβ42 peptides
appear to enhance HIV-1 attachment
and entry to promote productive
infection in susceptible cells of the
CNS (Widera et al., 2014).
(6) Toxoplasma and neurodegenera-
tion: Toxoplasma species such as
Toxoplasma gondii are intracellu-
lar protozoan parasites that can
cause encephalitis and neurological
dysfunction by promoting chronic
inflammation of the brain and
CNS. Recently AD has been asso-
ciated with significantly increased
anti-T. gondii antibodies suggest-
ing a possible mechanistic link
between T. gondii infection and AD
(Prandota, 2014).
(7) Viroids, miRNAs and AD: viroids
are minimalist plant pathogens that
consist of a viroid-specific ssRNA
that are remarkably similar to miR-
NAs in their mode of generation,
processing, structure and function,
mobility and ability to spread dis-
ease within the host (Hill et al.,
2009; Hill and Lukiw, 2014; Pogue
et al., 2014). Abundant research evi-
dence now strongly links miRNA
dysregulation with AD and repre-
sents a new class of biomarkers
which may be diagnostic for AD
(Alexandrov et al., 2012; Danborg
et al., 2014; Maffioletti et al., 2014).
We may be able to gain insight on
the mechanism of AD neuropathol-
ogy driven by miRNA from what is
already known about plant viroids
and their ability to spread systemic
degenerative disease (Navarro et al.,
2012; Hill et al., 2014; Pogue et al.,
2014).
(8) Hepatitis and AD: Hepatitis C virus
(HCV) is a small, enveloped ssRNA
virus of the family Flaviviridae
containing a ∼9600 nucleotide
genome that causes a chronic infec-
tious disease of the liver and is
associated with neuroimmune dis-
orders (Monaco et al., 2012). HCV
infection has recently been shown
to significantly increase the risk
for AD, especially in the aged
(Chiu et al., 2013; Karim et al.,
2014).
(9) Cytomegalovirus and AD: A grow-
ing number of common viruses
and latent viral infections involving
Herpesviridae have been linked to
the development of AD, and one of
these is the human cytomegalovirus
(HCMV). HCMV infection is often
unnoticed in healthy people, but
can be life-threatening for immune-
compromised, HIV-infected or
organ transplant patients. Recently
blood serum, cerebrospinal fluid,
and cryopreserved lymphocytes
from AD patients were analyzed for
associations between CMV infec-
tion and AD and it was found (i)
that CMV antibody levels were pos-
itively associated with the number
of NFT; (ii) that the percentage
of senescent T cells was signifi-
cantly higher for CMV-seropositive
as compared to CMV-seronegative
subjects, and (iii) that this was
associated with the pathologic
diagnosis of AD (Lurain et al.,
2013).
(10) GI tract and blood-brain bar-
rier permeability: Lastly and
importantly, the GI tract epithe-
lial barrier and the blood brain
barrier both become signifi-
cantly more permeable over
the course of aging (Brenner,
2013; Tran and Greenwood-Van
Meerveld, 2013). This may make
the CNS more susceptible to
potential neurotoxins generated by
microbiome-resident or environ-
mental pathogens. Environmental
and dietary influences, includ-
ing chronic bacterial or viral
infections can progressively alter
blood-brain barrier permeabil-
ity and thereby facilitate cerebral
colonization by opportunistic
pathogens as we age (Welling et al.,
2014).
Taken together, it is clear that the human
CNS is under constant assault by a
wide array of extrinsic and intrinsic neu-
rotrophic microbes and pathogens includ-
ing bacteria, virus, fungus, nucleic-acid
free prions, or small non-coding RNAs
found both in the environment and con-
tained within the microbiome. Virtually
every type of microbe known has been
implicated in contributing to the suscepti-
bility and pathogenesis of the AD process.
This may be especially important over the
course of aging because innate-immune
and physiological barriers are often com-
promised with age, enabling microbes
and/or their ‘neurotoxic secretions’ to
gain easier access to CNS compartments
(Brenner, 2013; Tran and Greenwood-
Van Meerveld, 2013; Welling et al., 2014).
Because AD is clearly a multifactorial dis-
ease, and there are multiple biological
pathways by which brain cells can dys-
function, perhaps it is not too surpris-
ing that multiple and complex microbial
insults could contribute to AD, includ-
ing the spreading of pathological signals
throughout the CNS (Alexandrov et al.,
2012; Bhattacharjee and Lukiw, 2013). The
contributions of microbes to multiple aspects
of human physiology and neurobiology in
health and disease have up until now not
been fully appreciated. Interestingly, both
the entorhinal cortex-hippocampal axis
and the olfactory system have been sug-
gested as the earliest anatomical regions
targeted by AD, indicating that perhaps
primary as well as opportunistic infec-
tions might contribute to AD pathogenesis
(Lazarov and Marr, 2010; Bhattacharjee
and Lukiw, 2013; Cross et al., 2013; Balin
and Hudson, 2014). What is currently
known is (i) that most neurological dis-
orders have a progressive, age-related and
geographical character; (ii) that the com-
position of the human microbiome and
exposure to pathogens changes with age,
diet, lifestyle, and biological environment;
and (iii) that microbial exposure, micro-
biome complexity and AD incidence are
highly variable in different human pop-
ulations (Yatsunenko et al., 2012; Lukiw,
2013; Danborg et al., 2014; Heintz and
Mair, 2014). Intelligent pharmacological
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approaches including anti-bacterial, anti-
viral and/or anti-inflammatory drugs in
combination, or drug strategies more
effectively directed toward the health and
homeostasis of the holobiome should be
useful in the future clinical management
of AD and related degenerative disor-
ders with an immune and inflammatory
component.
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